Who are Tramadol HCl/acetaminophen Extended Release's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tramadol hydrochloride/ Acetaminophen, placebo and tramadol, Tramadol hydrochloride/Acetaminophen Tab..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tramadol-hcl-acetaminophen-extended-release.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tramadol HCl/acetaminophen Extended Release — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tramadol HCl/acetaminophen Extended Release (Tramadol HCl/acetaminophen Extended Release) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic combination with NSAID alternative. Area: Pain Management.

marketed Opioid analgesic combination with NSAID alternative Mu-opioid receptor; norepinephrine transporter; serotonin transporter Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Tramadol HCl/acetaminophen Extended Release (Tramadol HCl/acetaminophen Extended Release) — Janssen Korea, Ltd., Korea. Tramadol inhibits norepinephrine and serotonin reuptake while acting as a weak opioid agonist, and acetaminophen reduces pain through central analgesic and antipyretic effects.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tramadol HCl/acetaminophen Extended Release TARGET	Tramadol HCl/acetaminophen Extended Release	Janssen Korea, Ltd., Korea	marketed	Opioid analgesic combination with NSAID alternative	Mu-opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol hydrochloride/ Acetaminophen	Tramadol hydrochloride/ Acetaminophen	Janssen Korea, Ltd., Korea	marketed	Opioid analgesic combination	Mu-opioid receptor; norepinephrine transporter; serotonin transporter
placebo and tramadol	placebo and tramadol	University of Southern Denmark	marketed	Opioid analgesic with monoamine reuptake inhibition	Mu-opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol hydrochloride/Acetaminophen Tab.	Tramadol hydrochloride/Acetaminophen Tab.	Daewon Pharmaceutical Co., Ltd.	phase 3	Opioid analgesic combination	Mu-opioid receptor; norepinephrine transporter; serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic combination with NSAID alternative class)

Janssen Korea, Ltd., Korea · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tramadol HCl/acetaminophen Extended Release — Competitive Intelligence Brief. https://druglandscape.com/ci/tramadol-hcl-acetaminophen-extended-release. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab